Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by State Board of Administration of Florida Retirement System

State Board of Administration of Florida Retirement System boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 12.1% in the 2nd quarter, HoldingsChannel reports. The fund owned 26,796 shares of the company’s stock after acquiring an additional 2,901 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Apellis Pharmaceuticals were worth $1,694,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. Harbor Investment Advisory LLC purchased a new position in Apellis Pharmaceuticals in the second quarter worth $30,000. Handelsbanken Fonder AB increased its position in shares of Apellis Pharmaceuticals by 4.7% in the second quarter. Handelsbanken Fonder AB now owns 13,400 shares of the company’s stock valued at $847,000 after buying an additional 600 shares in the last quarter. DAFNA Capital Management LLC increased its position in shares of Apellis Pharmaceuticals by 2.3% in the first quarter. DAFNA Capital Management LLC now owns 44,926 shares of the company’s stock valued at $1,928,000 after buying an additional 1,010 shares in the last quarter. Teacher Retirement System of Texas increased its position in shares of Apellis Pharmaceuticals by 17.8% in the second quarter. Teacher Retirement System of Texas now owns 7,344 shares of the company’s stock valued at $464,000 after buying an additional 1,112 shares in the last quarter. Finally, FORA Capital LLC purchased a new position in shares of Apellis Pharmaceuticals in the first quarter valued at $59,000. Hedge funds and other institutional investors own 74.28% of the company’s stock.

In other Apellis Pharmaceuticals news, Director Alec Machiels sold 2,500 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Thursday, July 15th. The stock was sold at an average price of $62.30, for a total transaction of $155,750.00. Following the sale, the director now directly owns 672,044 shares in the company, valued at approximately $41,868,341.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mark Jeffrey Delong sold 1,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, July 21st. The stock was sold at an average price of $65.00, for a total value of $65,000.00. Following the sale, the senior vice president now owns 10,490 shares in the company, valued at $681,850. The disclosure for this sale can be found here. Insiders have sold a total of 5,250 shares of company stock worth $331,810 over the last three months. 9.50% of the stock is currently owned by corporate insiders.

Apellis Pharmaceuticals stock opened at $31.40 on Friday. The stock’s 50 day moving average price is $55.97 and its 200 day moving average price is $53.48. The firm has a market capitalization of $2.73 billion, a PE ratio of -5.32 and a beta of 1.48. The company has a debt-to-equity ratio of 7.48, a quick ratio of 4.13 and a current ratio of 4.15. Apellis Pharmaceuticals, Inc. has a one year low of $27.50 and a one year high of $73.00.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Sunday, August 8th. The company reported ($2.72) EPS for the quarter, missing the consensus estimate of ($1.70) by ($1.02). The company had revenue of $0.62 million during the quarter, compared to analysts’ expectations of $2.26 million. On average, analysts forecast that Apellis Pharmaceuticals, Inc. will post -7.96 earnings per share for the current fiscal year.

A number of research firms recently commented on APLS. Raymond James upgraded Apellis Pharmaceuticals from an “outperform” rating to a “strong-buy” rating in a research report on Sunday, September 12th. Needham & Company LLC decreased their price target on Apellis Pharmaceuticals from $85.00 to $70.00 and set a “buy” rating on the stock in a research note on Friday, September 10th. Cowen raised their price target on Apellis Pharmaceuticals from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, July 1st. JPMorgan Chase & Co. raised their price target on Apellis Pharmaceuticals from $91.00 to $101.00 and gave the stock an “overweight” rating in a research note on Friday, July 2nd. Finally, Wedbush lowered Apellis Pharmaceuticals from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $71.00 to $39.00 in a research note on Friday, September 10th. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals has an average rating of “Buy” and an average price target of $70.44.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Featured Story: What are the advantages of the Stochastic Momentum Index?

Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS).

Institutional Ownership by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.